reports
Beyond Air Schedules Fiscal Year End 2025 Financial Results Conference...
Beyond Air Schedules Fiscal Year End 2025 Financial Results Conference Call and Webcast GARDEN CITY, N.Y., May 20, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced that it will report financial results for its fiscal fourth quarter and full year ended March 31, 2025 on Tuesday, June 17, 2025. The Company's management team is scheduled to host a conference call and webcast at 4:30 pm E...
Medicare Boosts Reimbursement for Oncocyte’s Flagship Technology
Medicare Boosts Reimbursement for Oncocyte’s Flagship Technology New price of $2,753 for the GraftAssureCore™ assay increases total addressable market size and margin opportunityBrings pricing in line with existing competitive technologyExpands market appeal for prospective FDA-cleared kitted product at transplant centers IRVINE, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp., (Nasdaq: OCX), a diagnostics technology company, today provided a positive update on pricing for its next-generation lab-developed test (LDT), GraftAssureCore. The new reimbursement rate strengthens the co...
- Wedbush Research
XENE XENON PHARMACEUTICALS INC
WDC WESTERN DIGITAL CORPORATION
TSLA TESLA INC
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
PSTG PURE STORAGE INC. CLASS A
OFC CORPORATE OFFICE PROPERTIES TRUST
NVDA NVIDIA CORPORATION
NTAP NETAPP INC.
MU MICRON TECHNOLOGY INC.
INTC INTEL CORPORATION
GPRO GOPRO INC. CLASS A
GOOGL ALPHABET INC. CLASS A
FB FACEBOOK INC. CLASS A
BZH BEAZER HOMES USA INC.
AXTI AXT INC.
DHI D.R. HORTON INC.
2330 TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
BLDR BUILDERS FIRSTSOURCE INC.
TMHC TAYLOR MORRISON HOME CORPORATION
ARGX ARGENX ADS
ISR ISORAY
AMZN AMAZON.COM INC.
AMD ADVANCED MICRO DEVICES INC.
GM GENERAL MOTORS COMPANY
AAPL APPLE INC.
RCKT ROCKET PHARMACEUTICALS
MSFT MICROSOFT CORPORATION
SMCI SUPER MICRO COMPUTER
BDTX INC.
LSEA BLACK DIAMOND THERAPEUTICS
IMNM LANDSEA HOMES CORP (A)
STX IMMUNOME
GFS SEAGATE TECHNOLOGY HLDGS PLC
MLTX GLOBALFOUNDRIES INC
GETY MOONLAKE IMMUNOTHERAPEUTICS
DNTH GETTY IMAGES HOLDINGS INC
MXL-US DIANTHUS THERAPEUTICS INC
SDHC-US MAXLINEAR
INC.
SMITH DOUGLAS HOMES CORP.
- Jay McCanless
Landsea Homes Reports First Quarter 2025 Results
Landsea Homes Reports First Quarter 2025 Results Home sales revenue increased 2.3% to $299.4 millionNew home deliveries increased 27.3% to 643 homesNet new home orders of 679 increased 11.1%Home sales gross margin of 13.0%, adjusted home sales gross margin of 20.0%Book value per share of $18.14 DALLAS, May 12, 2025 (GLOBE NEWSWIRE) -- Landsea Homes Corporation (Nasdaq: LSEA) (“Landsea Homes” or the “Company”) announced today financial results for the first quarter ended March 31, 2025. For the quarter, the Company reported pretax loss of $9.9 million, net loss of $7.1 million or $0.20 ...
Team, Inc. Reports First Quarter 2025 Results
Team, Inc. Reports First Quarter 2025 Results SUGAR LAND, Texas, May 12, 2025 (GLOBE NEWSWIRE) -- Team, Inc. (NYSE: TISI) (“TEAM” or the “Company”), a global, leading provider of specialty industrial services offering customers access to a full suite of conventional, specialized, and proprietary mechanical, heat-treating, and inspection services, today reported its financial results for the quarter ended March 31, 2025. First Quarter 2025 Highlights: Generated first quarter 2025 revenue of $198.7 million and a gross margin of 23.8%.Reported a net loss of $29.7 million, inclusive of a $1...
Oncocyte Reports Q1 2025 Results and Business Progress
Oncocyte Reports Q1 2025 Results and Business Progress Q1 2025 pharma services revenue of $2.1 million, at 62% gross marginThree of the top 10 U.S. transplant centers expected to participate in clinical trialTen globally leading transplant hospitals are now using our GraftAssure research-use-only kitsTo reflect our larger market opportunity, we plan to rename the company in Q2 IRVINE, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp. (Nasdaq: OCX), a diagnostics technology company, today published the following letter to shareholders in conjunction with its first quarter ...
Team, Inc. Announces Timing of First Quarter Earnings Release and Conf...
Team, Inc. Announces Timing of First Quarter Earnings Release and Conference Call SUGAR LAND, Texas, May 08, 2025 (GLOBE NEWSWIRE) -- Team, Inc. (NYSE: TISI) (“TEAM” or the “Company”), a global leading provider of specialty industrial services offering customers access to a full suite of conventional, specialized, and proprietary mechanical, heat-treating, and inspection services, today announced that it will issue its first quarter 2025 earnings release on Monday, May 12, 2025 after the close of trading on the New York Stock Exchange. TEAM will host a conference call to discuss its finan...
Oncocyte to Release First Quarter 2025 Results on May 12, 2025
Oncocyte to Release First Quarter 2025 Results on May 12, 2025 IRVINE, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp., (Nasdaq: OCX), a leading diagnostics technology company, today announced that it will report first quarter 2025 financial results after the market closes on Monday, May 12, 2025. Oncocyte will host a live Zoom webinar to discuss the company's financial results at 2:00 p.m. PT that same day. The live webinar to discuss financial results, followed by Q&A, will be accessible via registration at the following link: . An archived replay will be available after the c...
Landsea Homes Schedules First Quarter 2025 Earnings Release and Confer...
Landsea Homes Schedules First Quarter 2025 Earnings Release and Conference Call DALLAS, May 01, 2025 (GLOBE NEWSWIRE) -- Landsea Homes Corporation (Nasdaq: LSEA) announced today that the company intends to release its results for the first quarter of 2025 after the market closes on Monday, May 12, 2025, and to host a conference call on Tuesday, May 13, 2025, at 10:00 AM Eastern Time to discuss its financial results and conduct a question-and-answer session. Conference Call Details: Date: Tuesday, May 13, 2025Time: 10:00 AM Eastern TimeToll-free dial-in number: 800-343-4136International d...
Oncocyte Provides Positive Update on Clinical Trial Progress
Oncocyte Provides Positive Update on Clinical Trial Progress Central Institutional Review Board approved, final preparatory steps underway at first transplant centersThree of the top 10 U.S. transplant centers expected to participate in trialNearly 10% of annual U.S. transplant volume represented in trial site interestPreparing for final Q-sub FDA meeting ahead of clinical validation IRVINE, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp., (Nasdaq: OCX), a leading diagnostics technology company, today provided a positive update on its substantial progress toward initiating its...
Oncocyte’s Proprietary Assay Demonstrates Long-Term Clinical Validity
Oncocyte’s Proprietary Assay Demonstrates Long-Term Clinical Validity Transplantation Direct publication uses assay to identify rejection in patients up to 13 years post-transplant Robust data set of 131 patients with 151 kidney biopsies enrolled over four years at Charité University in BerlinSupports market expansion for testing of high-risk patient populationNew findings advance understanding of the biology of organ rejection IRVINE, Calif., April 29, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp., (Nasdaq: OCX), a leading diagnostics technology company, today announced the publicatio...
Beyond Air Granted U.S. Patent Covering Treatment of NTM Infections U...
Beyond Air Granted U.S. Patent Covering Treatment of NTM Infections Using gaseous Nitric Oxide (gNO) GARDEN CITY, N.Y., April 24, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 12,274,830. The issued patent gives the Company protection for its method of delivering gaseous nitric oxide (gNO) to a p...
NeuroNOS Granted FDA Orphan Drug Designation for Phelan-McDermid Syndr...
NeuroNOS Granted FDA Orphan Drug Designation for Phelan-McDermid Syndrome, a Neurodevelopmental Disorder Linked to Autism The FDA designation marks a significant milestone in the development of a novel treatment for a rare neurodevelopmental disorder Plan to initiate first-in-human U.S. clinical trials of lead drug candidate for treating ASD in 2026 BOSTON, April 21, 2025 (GLOBE NEWSWIRE) -- NeuroNOS, a biopharmaceutical company focused on developing treatments for autism and Alzheimer disorders, and a subsidiary of Beyond Air (NASDAQ: XAIR), today announced that the U.S. Food and Drug ...
NeuroNOS Appoints Nobel Prize Laureate, Professor Dan Shechtman, to Sc...
NeuroNOS Appoints Nobel Prize Laureate, Professor Dan Shechtman, to Scientific Advisory Board Professor Shechtman joins fellow Nobel Prize laureate Professor Roger Kornberg to advance the development of treatments for Autism Spectrum Disorder and Alzheimer’s Disease BOSTON, April 15, 2025 (GLOBE NEWSWIRE) -- NeuroNOS, a biopharmaceutical company focused on developing transformative treatments for Autism Spectrum Disorder (ASD) and Alzheimer’s disease (AD)conditions, and a subsidiary of Beyond Air (NASDAQ: XAIR), is proud to announce the appointment of Nobel Prize laureate, Professor Dan...
Beyond Air Publishes Article in Annals of the American Thoracic Societ...
Beyond Air Publishes Article in Annals of the American Thoracic Society Journal Highlighting NTM-PD Patients’ Ability to Safely Self-Administer High-Dose Intermittent iNO Treatments Using the LungFit™ GO at Home GARDEN CITY, N.Y., April 09, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced the publication of its scientific article, “A Pilot Study to Assess the Effect of Intermittent In...
GMS Inc: 1 director
A director at GMS Inc bought 3,650 shares at 70.000USD and the significance rating of the trade was 51/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showin...
Oncocyte to Participate in 24th Annual Needham Virtual Healthcare Conf...
Oncocyte to Participate in 24th Annual Needham Virtual Healthcare Conference IRVINE, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp. (Nasdaq: OCX), a leading diagnostics technology company, today announced that Chief Executive Officer Josh Riggs and Chief Financial Officer Andrea James will attend the 24th Annual Needham Virtual Healthcare Conference, taking place from April 7-10, 2025. In addition, CEO Josh Riggs will participate in a fireside chat at the conference. During the event, Josh and Andrea will discuss Oncocyte’s innovative diagnostic technologies and will highlight...
NeuroNOS Announces Groundbreaking Research Publication by its CSO Demo...
NeuroNOS Announces Groundbreaking Research Publication by its CSO Demonstrating Mechanism of Action in Alzheimer’s Disease and Reinforcing Platform’s Strength Across Neurological Disorders BOSTON, April 01, 2025 (GLOBE NEWSWIRE) -- NeuroNOS, a pioneering biopharmaceutical company developing transformative treatments for complex neurological disorders, including Autism Spectrum Disorder (ASD), brain cancers, and Alzheimer’s disease, and a subsidiary of Beyond Air (NASDAQ: XAIR), proudly announces the publication of breakthrough research by its Chief Scientific Officer, Prof. Haitham Amal, ...
Beyond Air Announces Vanderbilt University Medical Center as First Lum...
Beyond Air Announces Vanderbilt University Medical Center as First Luminary Site As the first Beyond Air luminary site, Vanderbilt will help evaluate and showcase the clinical and operational benefits of LungFit® PH, supporting broader awareness and adoption of tankless iNO technology GARDEN CITY, N.Y., March 31, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced that Vanderbilt Unive...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.